| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination
|
Chen, Jing
|
|
|
19 |
2 |
p. 349-357
|
artikel
|
| 2 |
Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021
|
Yang, Si
|
|
|
19 |
2 |
p. 441-459
|
artikel
|
| 3 |
Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets
|
Li, Yutong
|
|
|
19 |
2 |
p. 325-336
|
artikel
|
| 4 |
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis
|
Chen, Ke-qian
|
|
|
19 |
2 |
p. 483
|
artikel
|
| 5 |
Could the TAE score predicting the prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors be better if certain revisions are made?
|
Ma, Xijing
|
|
|
19 |
2 |
p. 484-485
|
artikel
|
| 6 |
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection
|
Zeng, Jianxing
|
|
|
19 |
2 |
p. 428-440
|
artikel
|
| 7 |
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
|
Weng, Meng-Tzu
|
|
|
19 |
2 |
p. 405-414
|
artikel
|
| 8 |
Enhancing the evaluation and management of MAFLD: a call for comprehensive assessments and social work integration
|
Wang, Han
|
|
|
19 |
2 |
p. 472-473
|
artikel
|
| 9 |
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
|
Hui, Rex Wan-Hin
|
|
|
19 |
2 |
p. 304-314
|
artikel
|
| 10 |
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study
|
Wang, Shao-Wen
|
|
|
19 |
2 |
p. 415-427
|
artikel
|
| 11 |
Global, regional, and national temporal trends in incidence and mortality for liver cancer due to hepatitis B, 1990–2021: a decomposition and age-period-cohort analysis for the Global Burden of Disease Study 2021
|
Li, Jinbo
|
|
|
19 |
2 |
p. 368-383
|
artikel
|
| 12 |
MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study
|
Vaz, Karl
|
|
|
19 |
2 |
p. 384-394
|
artikel
|
| 13 |
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions: Correspondence
|
Daungsupawong, Hinpetch
|
|
|
19 |
2 |
p. 478-479
|
artikel
|
| 14 |
Optimizing non-invasive monitoring of the therapeutic response to NSBBs in portal hypertension: is machine learning the answer?
|
Berzigotti, Annalisa
|
|
|
19 |
2 |
p. 302-303
|
artikel
|
| 15 |
Predicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices
|
Giuffrè, Mauro
|
|
|
19 |
2 |
p. 460-471
|
artikel
|
| 16 |
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
|
Tan, Zhili
|
|
|
19 |
2 |
p. 358-367
|
artikel
|
| 17 |
Reply to “Metabolic (dysfunction)-associated fatty liver disease metrics and contributions: Correspondence”
|
Suoh, Maito
|
|
|
19 |
2 |
p. 480-482
|
artikel
|
| 18 |
Response to the Liver transplantation for pediatric acute liver failure: Need to think beyond King’s College hospital criteria and etiology!
|
Pamecha, Viniyendra
|
|
|
19 |
2 |
p. 476-477
|
artikel
|
| 19 |
Role of liver-resident NK cells in liver immunity
|
Pan, Zheng
|
|
|
19 |
2 |
p. 315-324
|
artikel
|
| 20 |
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study
|
Kuo, Chia-Chih
|
|
|
19 |
2 |
p. 395-404
|
artikel
|
| 21 |
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
|
Eslam, Mohammed
|
|
|
19 |
2 |
p. 261-301
|
artikel
|
| 22 |
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease
|
Elangovan, Harendran
|
|
|
19 |
2 |
p. 337-348
|
artikel
|
| 23 |
What is the truth: the roles of macrophages in EBV-LELCC
|
Huang, Silan
|
|
|
19 |
2 |
p. 474-475
|
artikel
|
Tijdschrift beschrijving